Sanofi (ETR:SNW)

Germany flag Germany · Delayed Price · Currency is EUR
80.15
+0.93 (1.17%)
Feb 2, 2026, 2:24 PM CET
-23.07%
Market Cap95.74B -22.4%
Revenue (ttm)46.72B +5.5%
Net Income7.81B +40.5%
EPS6.40 +44.2%
Shares Outn/a
PE Ratio12.25
Forward PE9.46
Dividend3.92 (4.95%)
Ex-Dividend DateMay 12, 2025
Volume15,592
Average Volume20,324
Open79.41
Previous Close79.22
Day's Range79.29 - 80.47
52-Week Range76.43 - 110.82
Beta0.40
RSI49.04
Earnings DateJan 29, 2026

About Sanofi

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]

Sector Healthcare
Founded 1994
Employees 82,878
Stock Exchange Deutsche Börse Xetra
Ticker Symbol SNW
Full Company Profile

Financial Performance

In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.

Financial Statements

News

Sanofi (SNY) Gains Positive EU Nod for Rezurock Approval

Sanofi (SNY) Gains Positive EU Nod for Rezurock Approval

2 days ago - GuruFocus

Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News

This vaccine-focused biotech reported a significant insider sale as it advances its hepatitis B franchise and global partnerships.

2 days ago - The Motley Fool

Sanofi Announces Positive CHMP Opinion For Rezurock In EU

PARIS (dpa-AFX) - Sanofi (SNY), Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the condi...

3 days ago - Finanz Nachrichten

Sanofi (SNY) Gains EU Panel Support for Rezurock Approval

Sanofi (SNY) Gains EU Panel Support for Rezurock Approval

3 days ago - GuruFocus

Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease

Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world ev...

3 days ago - GlobeNewsWire

Sanofi SA (SNY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...

Sanofi SA (SNY) Q4 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Acquisitions Propel Performance

3 days ago - GuruFocus

Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript

Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript

3 days ago - Seeking Alpha

Q4 2025 Sanofi SA Earnings Call Transcript

Q4 2025 Sanofi SA Earnings Call Transcript

3 days ago - GuruFocus

Sanofi Creeps Higher On 'Essentially In Line' Guidance For 2026

Sanofi stock rose slightly early Thursday on better-than-expected earnings and in line guidance for the current year.

3 days ago - Investor's Business Daily

Sanofi (SNY) Projects Profitable Growth and Announces Share Buyback for 2026

Sanofi (SNY) Projects Profitable Growth and Announces Share Buyback for 2026

4 days ago - GuruFocus

Sanofi (SNY) Reports Strong EPS Growth and Sales Performance

Sanofi (SNY) Reports Strong EPS Growth and Sales Performance

4 days ago - GuruFocus

Sanofi Warns Dupixent Is Too Big To Replace As Patent Clock Ticks

Sanofi SA (NASDAQ: SNY) reported fourth-quarter sales of $13.159 billion (11.30 billion euros) on Thursday, missing the consensus of $13.41 billion . Sales increased 7% year over year, up 13.3% in co...

4 days ago - Benzinga

Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite

Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, th...

4 days ago - CNBC

Earnings Scheduled For January 29, 2026

Companies Reporting Before The Bell • MOGU (NYSE: MOGU) is estimated to report earnings for its first quarter. • Trane Technologies (NYSE: TT) is likely to report quarterly earnings at $2.82 per sha...

4 days ago - Benzinga

Sanofi (SNY) Surpasses Earnings Expectations with Strong Dupixent Sales

Sanofi (SNY) Surpasses Earnings Expectations with Strong Dupixent Sales

4 days ago - GuruFocus

Sanofi Posts Q4 Loss, Sees Continued Profitable Growth In FY26; Plans EUR 1 Bln Buyback

(RTTNews) - French drug major Sanofi (SNY) reported Thursday a loss in its fourth quarter, compared to prior year's profit, despite higher net sales. Looking ahead for fiscal 2026, the company still p...

4 days ago - Nasdaq

Sanofi to Launch $1.20 Billion Share Buyback

The buyback comes as the French drugmaker said that its sales and earnings for the fourth quarter rose.

4 days ago - WSJ

Sanofi (SNY) Reports Strong Q4 Earnings with Significant EPS and Revenue Beat

Sanofi (SNY) Reports Strong Q4 Earnings with Significant EPS and Revenue Beat

4 days ago - GuruFocus

Sanofi Non-GAAP EPS of €1.53 beats by €0.68, revenue of €11.3B beats by €170M; issues FY26 outlook

Sanofi press release (SNY): Q4 Non-GAAP EPS of €1.53 beats by €0.68. Revenue of €11.3B (+7.0% Y/Y) beats by €170M. Pharma launches increased sales by 49.4%

4 days ago - Seeking Alpha

Sanofi: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026

2025: strong sales and EPS growth.Continued profitable growth expected in 2026 Paris, January 29, 2026 Q4 sales growth of 13.3% at CER1 and business earnings per share (EPS)2 of €1.53 Pharma launc...

4 days ago - Finanz Nachrichten

Sanofi targets high single digit sales growth in 2026, plans share buyback

French drugmaker Sanofi said on Thursday it expects sales to grow by a high-single-digit percentage in 2026, banking on strong demand for its blockbuster asthma drug Dupixent and some newer medicines.

4 days ago - Reuters